Identification of bile biomarkers of biliary tract cancer through a liquid chromatography/mass spectrometry-based metabolomic method

Xu,Xiaofeng; Cheng,Shaobing; Ding,Chaofeng; Lv,Zhen; Chen,Deying; Wu,Jian; Zheng,Shusen

doi:10.3892/mmr.2014.2973

Identification of bile biomarkers of biliary tract cancer through a liquid chromatography/mass spectrometry-based metabolomic method

Authors:
- Xiaofeng Xu
- Shaobing Cheng
- Chaofeng Ding
- Zhen Lv
- Deying Chen
- Jian Wu
- Shusen Zheng
View Affiliations

Affiliations: Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, P.R. China, Collaborative Innovation Center of Diagnosis and Treatment of Infectious Diseases, Hangzhou, Zhejiang 310003, P.R. China
Published online on: November 18, 2014 https://doi.org/10.3892/mmr.2014.2973
Pages: 2191-2198

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The incidence and mortality rate of biliary tract cancer have been increasing worldwide; however, its diagnosis and prognosis have not improved in recent years. A novel approach, termed ‘metabolomics’, may have the potential to be developed as an effective diagnostic tool. The present study prospectively obtained bile samples from 115 individuals, including 32 patients with biliary tract cancer, 61 patients with benign biliary tract diseases and 22 normal controls. A liquid chromatography/mass spectrometry (LC/MS)‑based approach was used to investigate the differences in bile samples between the three groups, followed by multivariate statistical analysis, which included partial least squares projection to latent structures with discriminant analysis (PLS‑DA) and orthogonal projection to latent structures with discriminant analysis (OPLS‑DA). The metabolomic 2D score plot and 3D plot revealed clear separation between the cancer, benign and normal control groups by PLS‑DA. To further address the significant difficulties in clinically differentiating between biliary tract cancer and benign biliary tract diseases, OPLS‑DA was performed to distinguish between the two disease groups and to select potential biomarkers. The cancer and benign groups were well differentiated. The metabolic analysis revealed significantly lower levels of lysophosphatidylcholine, phenylalanine, 2‑octenoylcarnitine, tryptophan and significantly higher levels of taurine‑ and glycine‑conjugated bile acids in the bile from patients with biliary tract cancer compared with those in the bile from patients with benign biliary tract disease. The present study suggested that an LC/MS‑based metabolomic investigation provides a potent and promising approach for discriminating biliary tract cancer from benign biliary tract diseases and the identified specific metabolites may offer potential as novel biomarkers for the early detection of biliary tract cancer.

View Figures

View References

1	Ravi SC and Shimul AS: Malignant biliary disease. Sabiston Textbook of Surgery. Townsend CM, Beauchamp RD, Evers BM, et al: Saunders Elsevier; Philadelphia, PA: 2007
2	Taylor-Robinson SD, Toledano MB, Arora S, et al: Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 48:816–820. 2001. View Article : Google Scholar : PubMed/NCBI
3	Patel T: Worldwide trends in mortality from biliary tract malignancies. BMC Cancer. 2:102002. View Article : Google Scholar : PubMed/NCBI
4	Khan SA, Taylor-Robinson SD, Toledano MB, et al: Changing international trends in mortality rates for liver, biliary and pancreatic tumours. J Hepatol. 37:806–813. 2002. View Article : Google Scholar : PubMed/NCBI
5	Shaib Y and El-Serag HB: The epidemiology of cholangiocarcinoma. Semin Liver Dis. 24:115–125. 2004. View Article : Google Scholar : PubMed/NCBI
6	Khan SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet. 366:1303–1314. 2005. View Article : Google Scholar : PubMed/NCBI
7	Ueno N, Sano T, Kanamaru T, et al: Adenosquamous cell carcinoma arising from the papilla major. Oncol Rep. 9:317–320. 2002.PubMed/NCBI
8	Matsumoto A, Imamura M, Akagi Y, et al: A case report of disseminated recurrence of inferior bile duct carcinoma in PTCD fistula. Kurume Med J. 49:71–75. 2002. View Article : Google Scholar : PubMed/NCBI
9	Patel AH, Harnois DM, Klee GG, LaRusso NF and Gores GJ: The utility of CA19-9 in the diagnoses of cholangiocarcinoma in patients without primary sclerosing cholangitis. Am J Gastroenterol. 95:204–207. 2000. View Article : Google Scholar : PubMed/NCBI
10	Perkins GL, Slater ED, Sanders GK and Prichard JG: Serum tumor markers. Am Fam Physician. 68:1075–1082. 2003.PubMed/NCBI
11	Carpelan-Holmström M, Louhimo J, Stenman UH, Alfthan H and Haglund C: CEA, CA 19-9 and CA 72-4 improve the diagnostic accuracy in gastrointestinal cancers. Anticancer Res. 22:2311–2316. 2002.PubMed/NCBI
12	Harewood GC, Baron TH, Stadheim LM, et al: Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol. 99:1464–1469. 2004. View Article : Google Scholar : PubMed/NCBI
13	Malhi H and Gores GJ: Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther. 23:1287–1296. 2006. View Article : Google Scholar : PubMed/NCBI
14	Wua H, Xue R, Lub C, et al: Metabolomic study for diagnostic model of oesophageal cancer using gas chromatography/mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 877:3111–3117. 2009. View Article : Google Scholar
15	Wu H, Xue R, Dong L, et al: Metabolomic profiling of human urine in hepatocellular carcinoma patients using gas chromatography/mass spectrometry. Anal Chim Acta. 648:98–104. 2009. View Article : Google Scholar : PubMed/NCBI
16	Bogdanov M, Matson WR, Wang L, et al: Metabolomic profiling to develop blood biomarkers for Parkinson’s disease. Brain. 131:389–396. 2008. View Article : Google Scholar : PubMed/NCBI
17	Goodacre R, Vaidyanathan S, Dunn WB, Harrigan GG and Kell DB: Metabolomics by numbers: acquiring and understanding global metabolite data. Trends Biotechnol. 22:245–252. 2004. View Article : Google Scholar : PubMed/NCBI
18	Claudino WM, Quattrone A, Biganzoli L, et al: Metabolomics: available results, current research projects in breast cancer, and future applications. J Clin Oncol. 25:2840–2846. 2007. View Article : Google Scholar : PubMed/NCBI
19	Chen F, Xue J, Zhou L, Wu S and Chen Z: Identification of serum biomarkers of hepatocarcinoma through liquid chromatography/mass spectrometry-based metabonomic method. Anal Bioanal Chem. 401:1899–1904. 2011. View Article : Google Scholar : PubMed/NCBI
20	OuYang D, Xu J, Huang H and Chen Z: Metabolomic profiling of serum from human pancreatic cancer patients using 1 H NMR spectroscopy and principal component analysis. Appl Biochem Biotechnol. 165:148–154. 2011. View Article : Google Scholar : PubMed/NCBI
21	Lu N, Wei D, Chen F and Yang ST: Lipidomic profiling and discovery of lipid biomarkers in snow alga Chlamydomonas nivalis under salt stress. Eur J Lipid Sci Technol. 114:253–265. 2012. View Article : Google Scholar
22	Yan XJ, Xu JL, Chen JJ, et al: Lipidomics focusing on serum polar lipids reveals species dependent stress resistance of fish under tropical storm. Metabolomics. 8:299–309. 2012. View Article : Google Scholar
23	Wiklund S, Johansson E, Sjöström L, et al: Visualization of GC/TOF-MS based metabolomics data for identification of biochemically interesting compounds using OPLS class models. Anall Chem. 80:115–122. 2008. View Article : Google Scholar
24	Chen DY, Yan XJ, Xu JL, et al: Lipidomic profiling and discovery of lipid biomarkers in Stephanodiscus sp under cold stress. Metabolomics. 9:949–959. 2013. View Article : Google Scholar
25	Zhang X, Choi FF, Zhou Y, et al: Metabolite profiling of plasma and urine from rats with TNBS-induced acute colitis using UPLC-ESI-QTOF-MS-based metabonomics - a pilot study. FEBS J. 279:2322–2338. 2012. View Article : Google Scholar : PubMed/NCBI
26	Liu YT, Jia HM, Chang X, et al: Metabolic pathways involved in Xin-Ke-Shu protecting against myocardial infarction in rats using ultra high-performance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry. J Pharm Biomed Anal. 90:35–44. 2014. View Article : Google Scholar
27	Harewood GC, Baron TH, Stadheim LM, et al: Prospective, blinded assessment of factors influencing the accuracy of biliary cytology interpretation. Am J Gastroenterol. 99:1464–1469. 2004. View Article : Google Scholar : PubMed/NCBI
28	Malhi H and Gores GJ: Review article: the modern diagnosis and therapy of cholangiocarcinoma. Aliment Pharmacol Ther. 23:1287–1296. 2006. View Article : Google Scholar : PubMed/NCBI
29	de Bellis M, Fogel EL, Sherman S, et al: Influence of stricture dilation and repeat brushing on the cancer detection rate of brush cytology in the evaluation of malignant biliary obstruction. Gastrointest Endosc. 58:176–182. 2003. View Article : Google Scholar : PubMed/NCBI
30	Mahmoudi N, Enns R, Amar J, et al: Biliary brush cytology: factors associated with positive yields on biliary brush cytology. World J Gastroenterol. 14:569–573. 2008. View Article : Google Scholar : PubMed/NCBI
31	Dunn WB, Bailey NJ and Johnson HE: Measuring the metabolome: current analytical technologies. Analyst. 130:606–625. 2005. View Article : Google Scholar : PubMed/NCBI
32	Wilson ID, Plumb R, Granger J, et al: HPLC-MS-based methods for the study of metabonomics. J Chromatogr B Analyt Technol Biomed Life Sci. 817:67–76. 2005. View Article : Google Scholar : PubMed/NCBI
33	Wen H, Yoo SS, Kang J, et al: A new NMR-based metabolomics approach for the diagnosis of biliary tract cancer. J Hepatol. 52:228–233. 2010. View Article : Google Scholar
34	Sharif AW, Williams HR, Lampejo T, et al: Metabolic profiling of bile in cholangiocarcinoma using in vitro magnetic resonance spectroscopy. HPB (Oxford). 12:396–402. 2010. View Article : Google Scholar
35	AbdAlla MSH, Taylor-Robinson SD, Sharif AW, et al: Differences in phosphatidylcholine and bile acids in bile from Egyptian and UK patients with and without cholangiocarcinoma. HPB (Oxford). 13:385–390. 2011. View Article : Google Scholar
36	Helmberger H, Hellerhoff K, Rüll T and Rösch T: Chronic infections of the biliary system. Radiologe. 40:530–536. 2000.(In German). View Article : Google Scholar : PubMed/NCBI
37	Albiin N, Smith IC, Arnelo U, et al: Detection of cholangiocarcinoma with magnetic resonance spectroscopy of bile in patients with and without primary sclerosing cholangitis. Acta Radiol. 49:855–862. 2008. View Article : Google Scholar : PubMed/NCBI
38	Billah M and Anthes J: The regulation and cellular functions of phosphatidylcholine hydrolysis. Biochem J. 269:281–291. 1990.PubMed/NCBI
39	van Helvoort A, Smith A, Sprong H, et al: MDR1 P-glycoprotein is a lipid translocase of broad specificity, while MDR3 P-glycoprotein specifically translocates phosphatidylcholine. Cell. 87:507–517. 1996. View Article : Google Scholar : PubMed/NCBI
40	Barrios JM and Lichtenberger LM: Role of biliary phosphatidylcholine in bile acid protection and NSAID injury of the ileal mucosa in rats. Gastroenterology. 118:1179–1186. 2000. View Article : Google Scholar : PubMed/NCBI
41	Komichi D, Tazuma S, Nishioka T, et al: Unique inhibition of bile salt-induced apoptosis by lecithins and cytoprotective bile salts in immortalized mouse cholangiocytes. Dig Dis Sci. 48:2315–2322. 2003. View Article : Google Scholar
42	Komichi D, Tazuma S, Nishioka T, et al: Glycochenodeoxycholate plays a carcinogenic role in immortalized mouse cholangiocytes via oxidative DNA damage. Free Radic Biol Med. 39:1418–1427. 2005. View Article : Google Scholar : PubMed/NCBI
43	Alpini G, Invernizzi P, Gaudio E, et al: Serotonin metabolism is dysregulated in cholangiocarcinoma, which has implications for tumor growth. Cancer Res. 68:9184–9193. 2008. View Article : Google Scholar : PubMed/NCBI
44	Zhang A, Sun H, Han Y, et al: Exploratory urinary metabolic biomarkers and pathways using UPLC-Q-TOF-HDMS coupled with pattern recognition approach. Analyst. 137:4200–4208. 2012. View Article : Google Scholar : PubMed/NCBI
45	Yang S, Minkler P and Hoppel C: cis-3,4-Methylene-heptanoylcarnitine: characterization and verification of the C8:1 acylcarnitine in human urine. J Chromatogr B Analyt Technol Biomed Life Sci. 857:251–258. 2007. View Article : Google Scholar : PubMed/NCBI
46	Trauner M, Fickert P and Wagner M: MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. Semin Liver Dis. 27:77–98. 2007. View Article : Google Scholar : PubMed/NCBI
47	Mauad TH, van Nieuwkerk CM, Dingemans KP, et al: Mice with homozygous disruption of the mdr2 P-glycoprotein gene. A novel animal model for studies of nonsuppurative inflammatory cholangitis and hepatocarcinogenesis. Am J Pathol. 145:1237–1245. 1994.PubMed/NCBI
48	Saintigny Y, Dumay A, Lambert S and Lopez B: A novel role for the Bcl-2 protein family: specific suppression of the RAD51 recombination pathway. EMBO J. 20:2596–2607. 2001. View Article : Google Scholar : PubMed/NCBI